Abstract
rmetHuG-CSF is the recombinant version of natural granulocyte colony-stimulating factor, the dominant stimulator in the production of neutrophilic leukocytes (neutrophils). Neutrophils represent the first line of defense against invading pathogens and when neutrophil numbers are suppressed by cancer chemotherapy, patients become liable to life-threatening infections.
The clearance of rmetHuG-CSF is effected by a combination of neutrophil mediated degradation and renal filtration. Site-directed addition of a single, linear PEG molecule yielded a form of G-CSF (pegfilgrastim) that was shown to be resistant to renal elimination yet remained sensitive to neutrophilmediated destruction. This semi-synthetic cytokine drug can persist in the plasma for extended periods in neutropenic conditions, yet is cleared rapidly when neutrophils recover. This lends a degree of automation to the therapeutic control of neutrophil numbers which has been exploited in clinical practice since its approval for human use in 2002.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nicola NA, Begley CG, Metcalf D (1985) Identification of the human analog of a regulator that induces differentiation in murine leukemic cells. Nature 314: 625–628
Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 61–65
Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H (1986) Molecular cloning and expression of cDNA for human granulocyte colonystimulating factor. Nature 319: 415–418
Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. British Journal of Cancer 56: 809–813
Gabrilove JL, Jakubowski A, Fain K, Grous J, Scher H, Sternberg C, Yagoda A, Clarkson B, Bonilla MA, Oettgen HF (1988) Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. Journal of Clinical Investigation 82: 1454–1461
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine 318: 1414–1422
Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R (1988) Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–672
Ono M (1994) Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). European Journal of Cancer 30A: Suppl-111
Uzumaki H, Okabe T, Sasaki N, Hagiwara K, Takaku F, Tobita M, Yasukawa K, Ito S, Umezawa Y (1989) Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proceedings of the National Academy of Sciences of the United States of America 86: 9323–9326
Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM (1990) Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 76: 2153–2158
Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim G-CSF on platelet recovery after high-dose chemotherapy. Lancet 339: 640–644
Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. Journal of Clinical Oncology 7: 1554–1562
Di Leo A, Bajetta E, Nole F, Biganzoli L, Ferrari L, Oriana S, Riboldi G, Bohm S, Spatti G, Raspagliesi F (1994) The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. British Journal of Cancer 69: 961–966
Tanaka H, Tokiwa T (1990) Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay. Journal of Pharmacology & Experimental Therapeutics 255: 724–729
Tanaka H, Kaneko T (1992) Pharmacokinetic and pharmacodynamic comparisons between human granulocyte colony-stimulating factor purified from human bladder carcinoma cell line 5637 culture medium and recombinant human granulocyte colony-stimulating factor produced in Escherichia coli. Journal of Pharmacology & Experimental Therapeutics 262: 439–444
Eliason JF, Greway A, Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, Horii I (2000) Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells (Miamisburg) 18: 40–45
Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE (1993) Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. Journal of Pediatrics 123: 471–479
Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J (1995) Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. Journal of Clinical Investigation 95: 2973–2978
Marsh JC, Gibson FM, Prue RL, Bowen A, Dunn VT, Hornkohl AC, Nichol JL, Gordon-S mith EC (1996) Serum thrombopoietin levels in patients with aplastic anaemia. British Journal of Haematology 95: 605–610
Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR (1996) Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87: 4068–4071
Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller GA, de Sauvage FJ, Eaton D (1997) Human platelets as a model for the binding and degradation of thrombopoietin. Blood 89: 2782–2788
Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology & Experimental Therapeutics 283: 520–527
Redman BG, Flaherty L, Chou TH, Kraut M, Martino S, Simon M, Valdivieso M, Groves E (1992) Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. Journal of Immunotherapy 12: 50–54
Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD (1994) Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. Journal of Pharmacology & Experimental Therapeutics 268: 152–158
Layton JE, Hockman H, Sheridan WP, Morstyn G (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74: 1303–1307
Shimazaki C, Uchiyama H, Fujita N, Araki S, Sudo Y, Yamagata N, Ashihara E, Goto H, Inaba T, Haruyama H (1995) Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Experimental Hematology 23: 1497–1502
Takatani H, Soda H, Fukuda M, Watanabe M, Kinoshita A, Nakamura T, Oka M (1996) Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrobial Agents & Chemotherapy 40: 988–991
Stute N, Santana VM, Rodman J H, Schell MJ, Ihle JN, Evans WE (1992) Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79: 2849–2854
Sturgill MG, Huhn RD, Drachtman RA, Ettinger AG, Ettinger LJ (1997) Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neu-trophil count with repeated dosing. American Journal of Hematology 54: 124–130
Briddell R, Stonev G, Molineux G (2001) Investigation of the mode of clearance of filgrastim and filgrastim SD/01 by human peripheral blood neutrophils in vitro. Experimental Hematology 29
Tanaka H, Tokiwa T (1990) Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor krn-8601 in the rat. Cancer Research 50:6615–6619
Kuwabara T, Ishikawa Y, Kobayashi H, Kobayashi S, Sugiyama Y (1995) Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharmaceutical Research 12: 1466–1469
Tanaka J, Miyake T, Shimizu T, Wakayama T, Tsumori M, Koshimura K, Murakami Y, Kato Y (2002) Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: A feasibility study. International Journal of Hematology 75: 489–492
Furuya H, Wakayama T, Ohguni S, Yamauchi K, Tanaka J, Hatazoe T, Kato Y (1995) Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin’s lymphoma receiving chemotherapy. International Journal of Hematology 61: 123–129
Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer serum half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematology 31: 290–299
Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I (2004) Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology 32: 1146–1155
Heatherington AC, Schuller J, Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. British Journal of Cancer 84: Suppl-6
Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu M-L, Hirsch J, Mahoney A, Carrell J, Boyd E et al. (2002) AlbugraninTM, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharmaceutical Research 19: 1720–1729
Jensen-Pippo KE, Whitcomb KL, Deprince RB, Ralph L, Habberfield AD (1996) Enternal bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharmaceutical Research (New York) 13: 102–107
Choi SH, Lee H, Park TG (2003) PEGylation of G-CSF using cleavable oligo-lactic acid linkage. Journal of Controlled Release 89: 271–284
DeFrees S, Wang Z-G, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden ECM et al. (2006) GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16: 833–843
Mueller H-J, Loening L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schuetz V, Henze G, da Palma JC, Ritter J et al. (2000) Pegylated asparaginase (OncasparTM) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology 110: 379–384
Melton A, Hershfield MS, Greenberg ML, Hatem C, Markert ML, Kurtzberg J, Abuchowski A, Buckley RH (1987) Treatment of adenosine deaminase-deficient severe combined immune deficiency ADA-SCID with polyethylene glycol-modified bovine adenosine deaminase PEG-ADA. Journal of Allergy & Clinical Immunology 79: 252
Karasiewicz R, Nalin C, Rosen P (1995) Peg-interferon conjugates. Official Gazette of the United States Patent & Trademark Office Patents: 17, 1995
Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, Ehrlich GK, Pan W, Xu Z-X, Modi MW et al. (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 12: 195–202
Malik F, Brew J, Maidment SA, Delgado C, Francis GE (2000) PEG-modified erythropoietin with improved efficacy. Experimental Hematology 28: 106
Sato H, Yamamoto K, Hayashi E, Takahara Y (2000) Transglutaminase-mediated dual and sitespecific incorporation poly(ethylene glycol) derivatives into a chimeric interleukin-2. Bioconjugate Chemistry 11: 502–509
Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T et al. (1995) Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86: 4486–4492
Jolling K, Ruixo JJP, Hemeryck A, Piotrovskij V, Greway T (2004) Population pharmacokinetic analysis of pegylated human erythropoietin in rats. Journal of Pharmaceutical Sciences 93: 3027–3038
Kuan C-T, Wang Q-C, Pastan I (1994) Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. Journal of Biological Chemistry 269: 7610–7616
Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proceedings of the National Academy of Sciences of the United States of America 97: 8548–8553
Benhar I, Wang Q-C, Fitzgerald D, Pastan I (1994) Pseudomonas exotoxin A mutants: Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. Journal of Biological Chemistry 269: 13398–13404
Gaertner HF, Offord RE (1996) Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chemistry 7: 38–44
Wang M, Lee LS, Nepomich A, Yang J-D, Conover C, Whitlow M, Filpula D (1 277) Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Engineering 11:1277–1283
Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ (1996) Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceutical Research 13: 996–1002
Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C (2002) Mono-N-terminal polyethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews 54(4): 477–485
Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA et al. (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Experimental Hematology 27: 1724–1734
Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang B-B, Gardner S, Miller-Messana MA, Shoemaker D et al. (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology 18:2522–2528
Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR et al. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 14: 29–35
Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I et al. (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology 20: 727–731
Yang B-B, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. Journal of Pharmaceutical Sciences 93: 1367–1373
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Molineux, G. (2009). Pegfilgrastim — designing an improved form of rmetHuG-CSF. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8679-5_10
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8678-8
Online ISBN: 978-3-7643-8679-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)